^
Association details:
Biomarker:REST signature
Cancer:Glioblastoma
Drug Class:Topoisomerase I inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

An expression based REST signature predicts patient survival and therapeutic response for glioblastoma multiforme

Excerpt:
...we developed an expression based REST signature and assessed its association with transcriptomics, genomics, drug sensitivity and clinical outcome for GBM in this article….cell lines with low REST activity were more sensitive to cytotoxic drugs including Mitomycin, Camptothecin and Cisplatin (Fig. 4A).
DOI:
10.1038/srep34556